Nicotinamide riboside

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1341-23-7

烟酰胺核糖

Nicotinamide riboside 是具有口服活性的 NAD⁺的前体，可以增加 NAD⁺水平并激活SIRT1和SIRT3。Nicotinamide riboside 是维生素 B3 (烟酸) 的来源，可以增强氧化代谢并防止高脂肪饮食诱导的代谢异常。Nicotinamide riboside 可以减少阿尔茨海默氏病转基因小鼠模型中的认知退化。

生物活性

Nicotinamide riboside, an orally active NAD⁺precursor, increases NAD⁺levels and activatesSIRT1andSIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities^[1]. Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease^[2].

IC₅₀& Target^[1]

SIRT1

SIRT3

Human Endogenous Metabolite

体外研究
(In Vitro)

Nicotinamide riboside (0.5 nM; 24 hours) reduces the acetylation status of Ndufa9 and SOD2^[1].
Nicotinamide riboside increases intracellular and mitochondrial NAD⁺content in C2C12, Hepa1.6, and HEK293 cells in a concentration-dependent manner at concentrations ranging from 1-1000 μM^[1].
Nicotinamide riboside boosts NAD to restore antiviral poly(ADP-ribose) polymerase (PARP) functions to support innate immunity for coronavirus (CoVs), a cause of COVID-19^[3].

Western Blot Analysis^[1]

Cell Line:	HEK293T cells
Concentration:	0.5 nM
Incubation Time:	24 hours
Result:	Reduced the acetylation status of Ndufa9 and SOD2.

体内研究
(In Vivo)

Chronic Nicotinamide riboside (p.o.; 400 mg/kg/day; for 16 weeks) supplementation increases plasma and intracellular NAD⁺content in a tissue-specific manner^[1].

Animal Model:	10-week-old C57Bl/6J mice^[1]
Dosage:	400 mg/kg
Administration:	p.o.; daily; for 16 weeks
Result:	Increased plasma and intracellular NAD⁺content in a tissue-specific manner.

Clinical Trial

分子量

255.25

Formula

C₁₁H₁₅N₂O₅

CAS 号

1341-23-7

中文名称

烟酰胺核糖

结构分类

Others

来源

milk

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.